The vascular effects of different arginase inhibitors in rat i/ated aorta and mesenteric arteries

British Journal of Pharmacology

Volumn 156, Issue 1, 2009, Pages 84-93

  Huynh, N N ^a   Harris, E E ^a   Chin Dusting, J F P ^a   Andrews, K L ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Aorta; Arginase; L arginine; Mesenteric arteries; Nitric oxide; Vasorelaxation

Indexed keywords

(2 BORONOETHYL)CYSTEINE; ACETYLCHOLINE; ARGINASE; ARGININE; CYSTEINE DERIVATIVE; EFLORNITHINE; N OMEGA HYDROXYNORARGININE; N(G) HYDROXYARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NORVALINE; UNCLASSIFIED DRUG; VALINE; (2 BORONOETHYL) CYSTEINE; (2-BORONOETHYL)-CYSTEINE; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; N(OMEGA) HYDROXYARGININE; N(OMEGA) HYDROXYNORARGININE; N(OMEGA)-HYDROXYARGININE; N(OMEGA)-HYDROXYNORARGININE; VASODILATOR AGENT;

ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL REACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TOLERANCE; ENDOTHELIUM; ENZYME INHIBITION; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS; TACHYPHYLAXIS; VASODILATATION; ANIMAL; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; IN VITRO STUDY; MALE; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; THORACIC AORTA; VASCULAR ENDOTHELIUM;

ACETYLCHOLINE; ANIMALS; AORTA, THORACIC; ARGINASE; ARGININE; BORONIC ACIDS; EFLORNITHINE; ENDOTHELIUM, VASCULAR; MALE; MESENTERIC ARTERIES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RATS; RATS, SPRAGUE-DAWLEY; TACHYPHYLAXIS; VALINE; VASODILATOR AGENTS;

EID: 65549138846     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2008.00036.x     Document Type: Article

References (51)

1. Abdul-Hussain MN, Jia YL, Hussain SNA (1996). Mechanisms mediating the vasodilatory effects of N-hydroxy-arginine in coronary arteries. Eur J Pharmacol 305 : 155 161.
2. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition (2008 revision). Br J Pharmacol 153 (Suppl. 2 S1 S209.
3. Bachetti T, Comini L, Francolini G, Bastianon D, Valetti B, Cadei M et al. (2004). Arginase pathway in human endothelial cells in pathophysiological conditions. J Mol Cell Cardiol 37 : 515 523.
4. Bagnost T, Berthelot A, Bouhaddi M, Laurant P, Andre C, Guillaume Y et al. (2008). Treatment with the arginase inhibitor N(omega)-hydroxy-nor-L- arginine improves vascular function and lowers blood pressure in adult spontaneously hypertensive rat. J Hypertens 26 : 1110 1118.
5. Berkowitz DE, White R, Li D, Minhas KM, Cernetich A, Kim S et al. (2003). Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 108 : 2000 2006.
6. Boucher JL, Custot J, Vadon S, Delaforge M, Lepoivre M, Tenu JP et al. (1994). N[omega]-Hydroxy-L-Arginine, an intermediate in the L-arginine to Nitric Oxide pathway, is a strong inhibitor of liver and macrophage arginase. Biochem Biophys Res Commun 203 : 1614 1621.
7. Buchwalow IB, Podzuweit T, Samoilova VE, Wellner M, Haller H, Grote S et al. (2004). An in situ evidence for autocrine function of NO in the vasculature. Nitric Oxide 10 : 203 212.
8. Buga GM, Singh R, Pervin S, Rogers NE, Schmitz DA, Jenkinson CP et al. (1996). Arginase activity in endothelial cells: inhibition by NG-hydroxy-L-arginine during high-output NO production. Am J Physiol 271 : H1988 98.
9. Cama E, Colleluori DM, Emig FA, Shin H, Kim SW, Kim NN et al. (2003a). Human arginase II: crystal structure and physiological role in male and female sexual arousal. Biochemistry 42 : 8445 8451.
10. Cama E, Emig FA, Ash DE, Christianson DW (2003b). Structural and functional importance of first-shell metal ligands in the binuclear manganese cluster of arginase I. Biochemistry 42 : 7748 7758.
11. Cederbaum SD, Yu H, Grody WW, Kern RM, Yoo P, Iyer RK (2004). Arginases I and II: do their functions overlap? Mol Genet Metab 81 : 38 44.
12. Chataigneau T, Feletou M, Huang PL, Fishman MC, Duhault J, Vanhoutte PM (1999). Acetylcholine-induced relaxation in blood vessels from endothelial nitric oxide synthase knockout mice. Br J Pharmacol 126 : 219 226.
13. Chen GF, Suzuki H (1990). Calcium dependency of the endothelium-dependent hyperpolarization in smooth muscle cells of the rabbit carotid artery. J Physiol 421 : 521 534.
14. Chicoine LG, Paffett ML, Young TL, Nelin LD (2004). Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol 287 : L60 L68.
15. Colleluori DM, Ash DE (2001). Classical and slow-binding inhibitors of human type II arginase. Biochemistry 40 : 9356 9362.
16. Cox JD, Cama E, Colleluori DM, Pethe S, Boucher JL, Mansuy D et al. (2001). Mechanistic and metabolic inferences from the binding of substrate analogues and products to arginase. Biochemistry 40 : 2689 2701.
17. Custot J, Moali C, Brollo M, Boucher JL, Delaforge M, Mansuy D et al. (1997). The new alpha-amino acid Nw- hydorxy-nor-L-arginine: a high -affinity inhibitor of arginase well adapted to bind to its manganese cluster. J Am Chem Soc 119 : 4086 4087.
18. Daghigh F, Fukuto JM, Ash DE (1994). Inhibition of rat liver arginase by an intermediate in NO biosynthesis, NG-hydroxy-L-arginine: implications for the regulation of nitric oxide biosynthesis by arginase. Biochem Biophys Res Commun 202 : 174 180.
19. Demougeot C, Prigent-Tessier A, Marie C, Berthelot A (2005). Arginase inhibition reduces endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats. J Hypertens 23 : 971 978.
20. Furchgott RF, Zawadzki JV (1980). The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 : 373 376.
21. Gold ME, Bush PA, Ignarro LJ (1989). Depletion of arterial L-arginine causes reversible tolerance to endothelium-dependent relaxation. Biochem Biophys Res Commun 164 : 714 721.
22. Hein TW, Zhang C, Wang W, Chang CI, Thengchaisri N, Kuo L (2003). Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J 17 : 2328 2330.
23. Hogan M, O'malley KD, Healy J, O'brien S, Bund SJ (2005). Implications for repetitive application of acetylcholine in the determination of the mechanisms of endothelium-dependent relaxation. Vascul Pharmacol 43 : 227 233.
24. Holan V, Pindjakova J, Krulova M, Neuwirth A, Fric J, Zajicova A (2006). Production of nitric oxide during graft rejection is regulated by the Th1/Th2 balance, the arginase activity, and L-arginine metabolism. Transplantation 81 : 1708 1715.
25. Hunter A, Downs DE (1945). The inhibition of arginase by amino acids. J Biol Chem 157 : 427 446.
26. Johnson FK, Johnson RA, Peyton KJ, Durante W (2005). Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension. Am J Physiol Regul Integr Comp Physiol 288 : R1057 R1062.
27. Khangulov SV, Pessiki PJ, Barynin VV, Ash DE, Dismukes GC (1995). Determination of the metal ion separation and energies of the three lowest electronic states of dimanganese (II,II) complexes and enzymes: catalase and liver arginase. Biochemistry 34 : 2015 2025.
28. Kim NN, Cox JD, Baggio RF, Emig FA, Mistry SK, Harper SL et al. (2001). Probing erectile function: S-(2-boronoethyl)-L-cysteine binds to arginase as a transition state analogue and enhances smooth muscle relaxation in human penile corpus cavernosum. Biochemistry 40 : 2678 2688.
29. Kimura M, Jefferis AM, Watanabe H, Chin-Dusting J (2002). Insulin inhibits acetylcholine responses in rat i/ated mesenteric arteries via a non-nitric oxide nonprostanoid pathway. Hypertension 39 : 35 40.
30. Lewis C, Zhu W, Pavkov ML, Kinney CM, Dicorleto PE, Kashyap VS (2008). Arginase blockade lessens endothelial dysfunction after thrombosis. J Vasc Surg 48 : 441 446.
31. Lewis TV, Dart AM, Chin-Dusting JP (1997). Non-specific inhibition by human lipoproteins of endothelium dependent relaxation in rat aorta may be attributed to lipoprotein phospholipids. Cardiovasc Res 34 : 590 596.
32. Li H, Meininger CJ, Hawker JR, Jr., Haynes TE, Kepka-Lenhart D, Mistry SK et al. (2001). Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 280 : E75 E82.
33. Ming XF, Barandier C, Viswambharan H, Kwak BR, Mach F, Mazzolai L et al. (2004). Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway. Implications for atherosclerotic endothelial dysfunction. Circ 110 : 3307 3314.
34. Morris CR, Vichinsky EP, Van Warmerdam J, Machado L, Kepka-Lenhart D, Morris SM et al. (2003). Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. J Pediatr Hematol Oncol 25 : 629 634.
35. Rodriguez S, Schleiffer R, Raul F, Richert L, Berthelot A (2004). How could aortic arginase activity enhancement be involved in DOCA-salt hypertension? Clin Exp Hypertens 26 : 1 12.
36. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M et al. (2008). Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 102 : 95 102.
37. Ryoo S, Lemmon CA, Soucy KG, Gupta G, White AR, Nyhan D et al. (2006). Oxidized low-density lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling. Circ Res 99 : 951 960.
38. Ryoo S, Gupta G, Benjo A, Lim HK, Camara A, Sikka G et al. (2008). Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res 102 : 923 932.
39. Sakai Y, Masuda H, Kihara K, Kurosaki E, Yamauchi Y, Azuma H (2004). Involvement of increased arginase activity in impaired cavernous relaxation with aging in the rabbit. J Urol 172 : 369 373.
40. Santhanam L, Lim HK, Miriel V, Brown T, Patel M, Balanson S et al. (2007). Inducible NO synthase dependent S-nitrosylation and activation of arginase1 contribute to age-related endothelial dysfunction. Circ Res 101 : 692 702.
41. Selamnia M, Mayeur C, Robert V, Blachier F (1998 alpha]- Difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells. Biochem Pharmacol 55 : 1241 1245.
42. Shimokawa H, Yasutake H, Fujii K, Owada MK, Nakaike R, Fukumoto Y et al. (1996). The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol 28 : 703 711.
43. Steppan J, Ryoo S, Schuleri KH, Gregg C, Hasan RK, White AR et al. (2006). Arginase modulates myocardial contractility by a nitric oxide synthase 1-dependent mechanism. Proc Natl Acad Sci USA 103 : 4759 4764.
44. Tenu J-P, Lepoivre M, Moali C, Brollo M, Mansuy D, Boucher J-L (1999). Effects of the new arginase inhibitor N[omega]-hydroxy-nor-arginine on NO synthase activity in murine macrophages. Nitric Oxide 3 : 427 438.
45. Thuraisingham RC, Roberts NB, Wilkes M, New DI, Mendes-Ribeiro AC, Dodd SM et al. (2002). Altered L-arginine metabolism results in increased nitric oxide release from uraemic endothelial cells. Clin Sci (Lond) 103 : 31 41.
46. Vetrovsky P, Boucher JL, Schott C, Beranova P, Chalupsky K, Callizot N et al. (2002). Involvement of NO in the endothelium-independent relaxing effects of N(omega)-hydroxy-L-arginine and other compounds bearing a C=NOH function in the rat aorta. J Pharmacol Exp Ther 303 : 823 830.
47. Wallace GC, Gulati P, Fukuto JM (1991). N[omega]-Hydroxy-L-arginine: a novel arginine analog capable of causing vasorelaxation in bovine intrapulmonary artery. Biochem Biophys Res Commun 176 : 528 534.
48. Wu CC, Chen SJ, Yen MH (1993). Different responses to acetylcholine in the presence of nitric oxide inhibitor in rat aortae and mesenteric arteries. Clin Exp Pharmacol Physiol 20 : 405 412.
49. Xu W, Kaneko FT, Zheng S, Comhair SA, Janocha AJ, Goggans T et al. (2004). Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 18 : 1746 1748.
50. Zhang C, Hein TW, Wang W, Chang CI, Kuo L (2001). Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J 15 : 1264 1266.
51. Zhang C, Hein TW, Wang W, Miller MW, Fossum TW, Mcdonald MM et al. (2004). Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 44 : 935 943.